Only a limited number of patients with amyloidosis and pulmonary hypertension have been reported in the literature. We report a 73-year-old female with AL type amyloidosis who developed respiratory insufficiency and right heart failure because of severe pulmonary hypertension. There were no signs of cardiac involvement with amyloid or findings consistent with interstitial lung disease. Previous reports of pulmonary hypertension without an apparent parenchymal lung or myocardial involvement with amyloidosis are summarized. Pulmonary hypertension due to deposition of amyloid in the pulmonary vasculature is an uncommon finding; however, it should be considered in cases of unexplained pulmonary hypertension in patients with amyloidosis.
Similar content being viewed by others
Reference
Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898–909
WHO-IUIS Nomenclature Sub-Committee. Nomenclature of amyloid and amyloidosis. Bull World Health Organ. 1993;71:105–12
Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenstrom’s macroglobulinemia. Hematology. 2004;257–82
Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis and therapy. Mayo Clin Proc. 1999;74:490–4
Kalova I, Niessen H. Amyloid in the cardiovascular system: a review. J Clin Pathol. 2005;58:125–33
Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis: the Mayo Clinic experience from 1980 to 1993. Ann Intern Med. 1996;124:407–13
Thompson PJ, Citron KM. Amyloid and the lower respiratory tract. Thorax. 1983;38:84–7
Gilmore JD, Hawkins PN. Amyloidosis and the respiratory tract. Thorax. 1999;54:444–51
Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655–65
Galie N, Manes A, Branzi A. Evaluation of pulmonary arterial hypertension. Curr Opin Cardiol. 2004;19:575–81
Antonioli E, Nozzoli C, Gianfaldoni G, Mannelli F, Rossi S, Betti S, Bernardeschi P, Fiorentini G, Bosi A. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Ann Oncol. 2005;16:1849–50
Hattori Y, Shimoda M, Okamoto S, Satoh T, Kakimoto T, Ikeda Y. Pulmonary hypertension and thalidomide therapy in multiple myeloma. Br J Haematol. 2003;121:191–2
Younis TH, Alam A, Paplham P, Spangenthal E, McCarthy P. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol. 2003;123:563
Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res. 2004;68:75–103
Crotty TB, Li CY, Edwards WD, Suman VJ. Amyloidosis and endomyocardial biopsy: correlation of extent and patterns of deposition with amyloid immunophenotype in 100 cases. Cardiovasc Pathol. 1994;5:39–42
Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc. 1984;59:547–55
Suwaidi JA, Velianou JL, Gertz MA, Cannon RO, Higano ST, Holmes DR. Systemic amyloidosis presenting with angina pectoris. Ann Int Med. 1999;131:838–41
Crawford F, Suo Z, Frang C, et al. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp Neurol. 1998;150:159–68
Chapman AD, Brown PA, Kerr KM. Right heart failure as the dominant clinical picture in a case of primary amyloidosis affecting the pulmonary vasculature. Scott Med J. 1999;44:116–17
Shiue ST, McNally DP. Pulmonary hypertension from prominent vascular involvement in diffuse amyloidosis. Arch Int Med. 1988;148:687–89
Dingli D, Utz JP, Gertz MA. Pulmonary hypertension in patients with amyloidosis. Chest. 2001;120:1735–8
Johnson WJ, Lie JT. Pulmonary hypertension and familial Mediterranean fever: a previously unrecognized association. Mayo Clin Proc. 1991;66:919–25
Lutz AE, Scneider U, Ehlerding G, Frenzel H, Koch KM, Kuhn K. Right ventricular cardiac failure and pulmonary hypertension in a long-term dialysis patient—unusual presentation of visceral beta 2-microglobulin amyloidosis. Nephrol Dial Transplant. 1995;10:555
McLaughlin WV, Shillington A. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477
Potential Financial Conflicts of Interest
None diclosed.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eder, L., Zisman, D., Wolf, R. et al. Pulmonary Hypertension and Amyloidosis—an Uncommon Association: A Case Report and Review of the Literature. J GEN INTERN MED 22, 416–419 (2007). https://doi.org/10.1007/s11606-006-0052-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11606-006-0052-9